Replies to post #22409 on MannKind Corp. (MNKD)

[lars1551]

"great" is a relative term. nothing performs or works better. the lack of adoption has nothing to do with effectiveness. Any argument against that is disingenuous. However, you are correct. It hasn't sold. A "black box" warning, insurance hurdles, an FDA process that took years longer than it should have, and lung function requirements, despite no evidence of lung issue wouldn't have played apart in that...would they? ha

Again, management was out classed at every turn other than development. There is value for those who invest now...IMO. But hey, it's a free market with endless opportunity. If you don't like this one find another. If you intend to short without a long position to hedge...good luck...you could wake up one morning looking for a tall building to jump off. I have a calculated risk that I have researched extensively. I';; take my loss, if need be, but I'll also take the risk/reward scenario that has presented itself.

GL

[SidVicious]

While Afrezza won't work for every diabetic, you fail to understand the reasons why those who started Afrezza didn't continue. The fact you don't know tells me you haven't really listened to management, especially Mike Castagna, who explained in detail the reasons.

There are a lot of factors that go into Rxing a drug. If you aren't educating your patients on how to correctly USE the drug, you'll fail in the market place. Mannkind made the mistake of trusting Sanofi. Never trust the French.